22nd Oct 2007

Vision RT has recently received 510(k) clearance from the FDA to market GateCT® and GateRT® as a class II medical device in the USA.  

GateCT® tracks the 3D surface of a patient in order to facilitate 4DCT data acquisition or prospective gated CT image data. GateRT® tracks respiratory motion in real time in order to gate radiation delivery or diagnostic imaging according to the breathing cycle. The systems are completely non invasive and do not require the application of external markers or any other physical device to the patient. The wealth of information derived by GateCT® and GateRT® from the tracked surface data of the patient provide the opportunity to perform advanced respiratory gating during radiation therapy.

Vision RT will be launching GateCT® and GateRT® at the ASTRO 2007 meeting in Los Angeles during the week commencing October 28th.

Company Background
Vision RT Limited is a UK based company that has developed a novel approach to enhance the crucial process of patient setup and surveillance during radiation therapy for the treatment of cancer. Vision RT’s revolutionary products, AlignRT®, GateCT® and GateRT® utilise a proprietary real-time 3D surface imaging technology to provide exceptional speed and accuracy designed to improve the efficacy and precision of radiation treatments. Further information on Vision RT and its products may be found on www.visionrt.com.